Supplementary Materials

Supplementary Material for:

P-selectin is a nanotherapeutic delivery target in the tumor microenvironment

Yosi Shamay, Moshe Elkabets, Hongyan Li, Janki Shah, Samuel Brook, Feng Wang, Keren Adler, Emily Baut, Maurizio Scaltriti, Prakrit V. Jena, Eric E. Gardner, John T. Poirier, Charles M. Rudin, José Baselga, Adriana Haimovitz-Friedman, Daniel A. Heller*

*Corresponding author. Email: hellerd{at}mskcc.org

Published 29 June 2016, Sci. Transl. Med. 8, 345ra87 (2016)
DOI: 10.1126/scitranslmed.aaf7374

This PDF file includes:

  • Fig. S1. Isotype controls and major genomic alterations.
  • Fig. S2. Nanoparticle characterization.
  • Fig. S3. In vitro and in vivo nanoparticle targeting studies.
  • Fig. S4. P-selectin and CD31 expression in irradiated and contralateral unirradiated tumors.
  • Fig. S5. Effect of ionizing radiation on P-selectin and nanoparticle localization.
  • Fig. S6. In vivo bioluminescence of metastatic models 7 days after treatments.
  • Fig. S7. B16F10 melanoma model assessments.
  • Fig. S8. Cytokine profile in the serum of healthy mice injected with FiPAX nanoparticles.
  • Fig. S9. P-selectin–targeted nanoparticle delivery of a MEK/ERK inhibitor.
  • Fig. S10. Kinetics of pERK inhibition in an HCT116 xenograft model.
  • Table S1. Nanoparticle sizes in nanometers, as measured by DLS.
  • Table S2. Complete blood count conducted 24 hours after intravenous administration of nanoparticles in healthy mice.

[Download PDF]